fda approves first oral glp-1 obesity drug august 14 2025 Wegovy Pill Wins FDA Approval

Tirzepatide), metabolic outcomes, and next-gen weight loss benefits

Compare semaglutide, tirzepatide, and retatrutide head to head

Learn about the benefits and practical steps for transitioning patients from GLP-1 RAs to dual GLP-1/GIP receptor agonists, such as tirzepatide, to improve glycemic control in adults with type 2 diabetes.

Semaglutide from $50 and Tirzepatide from $75

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D)

Adults with diabetes who used a GLP-1 receptor agonist after undergoing kidney transplantation had a decline in BMI and more stable measures of kidney function than those who did not use a GLP-1, according to a speaker